A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity
NCT06842186
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in adult with obesity, with or without Type 2 Diabetes (T2D and non-T2D, respectively). In addition, Part B includes two dose groups that will receive WVE-007 and tirzepatide in adults living with obesity and T2D.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Overweight and Obesity
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Wave Life Sciences USA, Inc.
- Last updated on ClinicalTrials.gov
- October 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- Parexel International-EPCU Baltimore · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.